227 related articles for article (PubMed ID: 28221724)
1. Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates.
Sirvent JA; Lücking U
ChemMedChem; 2017 Apr; 12(7):487-501. PubMed ID: 28221724
[TBL] [Abstract][Full Text] [Related]
2. Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR).
Ramachandran SA; Jadhavar PS; Singh MP; Sharma A; Bagle GN; Quinn KP; Wong PY; Protter AA; Rai R; Pham SM; Lindquist JN
Bioorg Med Chem Lett; 2017 Feb; 27(4):750-754. PubMed ID: 28131712
[TBL] [Abstract][Full Text] [Related]
3. Sulfoximines: a neglected opportunity in medicinal chemistry.
Lücking U
Angew Chem Int Ed Engl; 2013 Sep; 52(36):9399-408. PubMed ID: 23934828
[TBL] [Abstract][Full Text] [Related]
4. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
Sánchez-Martínez C; Lallena MJ; Sanfeliciano SG; de Dios A
Bioorg Med Chem Lett; 2019 Oct; 29(20):126637. PubMed ID: 31477350
[TBL] [Abstract][Full Text] [Related]
5. Symbiotic prodrugs (SymProDs) dual targeting of NFkappaB and CDK.
Rana S; Kour S; Sonawane YA; Robb CM; Contreras JI; Kizhake S; Zahid M; Karpf AR; Natarajan A
Chem Biol Drug Des; 2020 Aug; 96(2):773-784. PubMed ID: 32237047
[TBL] [Abstract][Full Text] [Related]
6. Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.
Poratti M; Marzaro G
Eur J Med Chem; 2019 Jun; 172():143-153. PubMed ID: 30978559
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG
Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832
[TBL] [Abstract][Full Text] [Related]
8. Application of sulfoximines in medicinal chemistry from 2013 to 2020.
Han Y; Xing K; Zhang J; Tong T; Shi Y; Cao H; Yu H; Zhang Y; Liu D; Zhao L
Eur J Med Chem; 2021 Jan; 209():112885. PubMed ID: 33227576
[TBL] [Abstract][Full Text] [Related]
9. Sulfoximines as ATR inhibitors: Analogs of VE-821.
Hendriks CMM; Hartkamp J; Wiezorek S; Steinkamp AD; Rossetti G; Lüscher B; Bolm C
Bioorg Med Chem Lett; 2017 Jun; 27(12):2659-2662. PubMed ID: 28479198
[TBL] [Abstract][Full Text] [Related]
10. The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer.
Lücking U; Jautelat R; Krüger M; Brumby T; Lienau P; Schäfer M; Briem H; Schulze J; Hillisch A; Reichel A; Wengner AM; Siemeister G
ChemMedChem; 2013 Jul; 8(7):1067-85. PubMed ID: 23671017
[TBL] [Abstract][Full Text] [Related]
11. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
Dietrich J; Hulme C; Hurley LH
Bioorg Med Chem; 2010 Aug; 18(15):5738-48. PubMed ID: 20621496
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Characterization of a Photoactivatable Caged Prodrug of Imatinib.
Zindler M; Pinchuk B; Renn C; Horbert R; Döbber A; Peifer C
ChemMedChem; 2015 Aug; 10(8):1335-8. PubMed ID: 26076342
[TBL] [Abstract][Full Text] [Related]
13. Polycyclic Sulfoximines as New Scaffolds for Drug Discovery.
Borst MLG; Ouairy CMJ; Fokkema SC; Cecchi A; Kerckhoffs JMCA; de Boer VL; van den Boogaard PJ; Bus RF; Ebens R; van der Hulst R; Knol J; Libbers R; Lion ZM; Settels BW; de Wever E; Attia KA; Sinnema PJ; de Gooijer JM; Harkema K; Hazewinkel M; Snijder S; Pouwer K
ACS Comb Sci; 2018 Jun; 20(6):335-343. PubMed ID: 29714998
[TBL] [Abstract][Full Text] [Related]
14. Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
Messina C; Messina M; Zanardi E
Ann Oncol; 2017 Dec; 28(12):3099-3100. PubMed ID: 28950333
[No Abstract] [Full Text] [Related]
15. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
Jing L; Tang Y; Xiao Z
Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.
Foote KM; Nissink JWM; McGuire T; Turner P; Guichard S; Yates JWT; Lau A; Blades K; Heathcote D; Odedra R; Wilkinson G; Wilson Z; Wood CM; Jewsbury PJ
J Med Chem; 2018 Nov; 61(22):9889-9907. PubMed ID: 30346772
[TBL] [Abstract][Full Text] [Related]
17. The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors.
Tang J; Lackey KE; Dickerson SH
Bioorg Med Chem Lett; 2013 Jan; 23(1):66-70. PubMed ID: 23218715
[TBL] [Abstract][Full Text] [Related]
18. 3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors.
Shen J; Li X; Zhang Z; Luo J; Long H; Tu Z; Zhou X; Ding K; Lu X
Chem Biol Drug Des; 2016 Nov; 88(5):690-698. PubMed ID: 27264434
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey.
Mariaule G; Belmont P
Molecules; 2014 Sep; 19(9):14366-82. PubMed ID: 25215591
[TBL] [Abstract][Full Text] [Related]
20. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
Namboodiri HV; Bukhtiyarova M; Ramcharan J; Karpusas M; Lee Y; Springman EB
Biochemistry; 2010 May; 49(17):3611-8. PubMed ID: 20337484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
